-

Incyte to Present at Upcoming Investor Conference

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Evercore ISI 4th Annual HealthCONx Conference (Virtual) on Tuesday, November 30, 2021 at 2:15 p.m. ET.

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Contacts

Incyte
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com

Industry:

Incyte

NASDAQ:INCY
Release Summary
Incyte to Present at Upcoming Investor Conference
Release Versions
English

Contacts

Incyte
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com

More News From Incyte

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

WILMINGTON, Del.--(BUSINESS WIRE)--New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated in Patients with MF & ET...

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

WILMINGTON, Del.--(BUSINESS WIRE)--Results from Incyte’s frontMIND Trial of Tafasitamab (Monjuvi/Minjuvi) Combination at the 2026 EHA Plenary Showed Prolonged Progression Free Survival...

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders...
Back to Newsroom